Trial reportHuman vaccines & immunotherapeutics2026
The mutual effects on safety and immunogenicity of combined vaccination with 15-valent pneumococcal conjugate vaccine and adsorbed acellular DPT in 3-month healthy infants: A randomized, open-label, controlled, phase III clinical trial.
Trial report in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the mutual effects on safety and immunogenicity of the combined vaccination of the 15-valent pneumococcal conjugate vaccine (PCV15) and the adsorbed acellular diphtheria-tetanus-pertussis combined vaccine (DTaP) in healthy infants aged 3 months (90 to 119 d) old. This phase III clinical trial enrolled 1110 subjects in Tangxian and Yutian County, Hebei Province, China. The total population was randomly divided into three groups on average: 370 infants received coadministration of PCV15 and DTaP at different sites (P+DTP group), 370 infants were vaccinated with PCV15 followed by DTaP after a 7-day interval (with a + 15-day window period) (P-DTP group), 370 infants were vaccinated with DTaP alone (DTap group). These 1110 subjects received the vaccine according to a 3-dose schedule of 0, 1, and 2 months. The antibody seropositivity rate, seroconversion rate, GMC, and the fold increase in GMC were reported for PCV15 and DTaP. The adverse events (AEs) within 30 minutes, solicited AEs from day 0 to day 30, unsolicited AEs from day 0 to day 30 after each dose were reported. Serious adverse events (SAEs) until 6 months after the whole dose were reported. The results showed that seroconversion rates and GMCs of DTaP in the P+DTP group were non-inferior to DTaP group. There was no significant difference in the positivity rate of IgG antibody between the P+DTP group and the P-DTP group. Except some serotypes (serotype 5, 6A, 6B, 9V, 12F, 23F), the differences in IgG antibody seroconversion rate between P+DTP group and P-DTP group were not statistically significant. Incidence of AEs in P+DTP group was lower than P-DTP group and slightly higher than DTaP group. Co-administration of PCV15 and DTaP showed no obvious interaction in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.